Categories
Reviews

J&J Single-Dose Covid-19 Vaccine Gains Backing From FDA Advisory Panel


Johnson & Johnson’s


JNJ -2.64%

single-dose Covid-19 vaccine worked safely and should be authorized for use in the U.S., a panel of experts advised federal health regulators Friday.

The advisory committee’s vote in support of the vaccine’s authorization is the last step before the U.S. Food and Drug Administration issues a decision, which is expected Saturday.

The panel, a group of 22 medical specialists in fields like internal medicine, pediatrics, vaccines and epidemiology, regularly advises the FDA about experimental vaccines. It voted to recommend shots from

Pfizer Inc.


PFE -0.98%

and partner

BioNTech


BNTX -2.94%

SE and

Moderna Inc.


MRNA 4.33%

before the agency authorized them in December.

During the all-day public meeting, representatives from the FDA and J&J discussed the safety and effectiveness of the company’s vaccine in a 44,000-plus subject study, as well as how effective the J&J vaccine is in preventing new cases caused by variants.

The give-and-take of questions and answers can be valuable in bolstering public confidence in the shot, according to FDA officials.

The vaccine was 66% effective at protecting people from moderate to severe Covid-19, an FDA review found, and even more effective at preventing severe disease alone.

“If authorized, Janssen’s vaccine candidate would play a pivotal role in the global effort to fight Covid-19,”

Johan Van Hoof,

global head of vaccines research at J&J’s Janssen pharmaceutical unit, said during the panel’s meeting. “A single-dose regimen offers the ability to vaccinate a population faster.”

As highly transmissible coronavirus variants sweep across the world, scientists are racing to understand why these new versions of the virus are spreading faster, and what this could mean for vaccine efforts. New research says the key may be the spike protein, which gives the coronavirus its unmistakable shape. Illustration: Nick Collingwood/WSJ

A rollout of the J&J vaccine could add enough shots in the U.S. by the end of March to boost the total number of people vaccinated by 20%. Health authorities are pushing to inoculate enough people as quickly as possible so that business, schools and other establishments can fully reopen.

SHARE YOUR THOUGHTS

How would you grade the vaccine rollout? Join the conversation below.

J&J has said it would deliver about 20 million doses for U.S. use by the end of March.

The FDA often convenes public meetings of outside experts to scrutinize experimental drugs, devices and vaccines up for agency approval, in part to boost public acceptance of the products should they be cleared for wide use.

J&J’s vaccine appeared to be safe in its pivotal study, the FDA found, aside from being effective.

“The known and potential benefits of Ad26 outweigh the known and potential risks,” Macaya Douoguih, head of clinical development and medical affairs at J&J’s Janssen unit, said during Friday’s meeting, using a code name for J&J’s vaccine.

FDA medical officer Yosefa Hefter said there are still unknowns about the vaccine, including the duration of immune protection and the safety and effectiveness in children.

An FDA analysis for the committee meeting also said rare cases of deep vein clots and of blockages in lung arteries were slightly more common in vaccine recipients than in placebo patients, and that the FDA considers these as “of clinical interest.”

The vaccine was effective “across demographic subgroups,” the FDA said. The demographic subgroups in the large study of J&J’s vaccines included racial and ethnic groups such as Black, Latino and Asian people, and age groups such as those 60 years and older.

Researchers also assessed efficacy in people who had underlying medical conditions including obesity and high blood pressure before entering the clinical trial. Sometimes vaccines don’t work as well in older people because of weakened immune systems.

One exception was that the vaccine appeared to be less effective in people 60 and older who had certain underlying medical conditions like diabetes and high blood pressure.

The Pfizer-BioNTech and Moderna vaccines also worked effectively across various demographic subgroups.

The vaccine was less effective in South Africa, where a more-transmissible Covid-19 variant has thrived, than in the U.S. J&J is among the companies working on new shots targeting the new strain, against which several current vaccines don’t appear to work as well.

J&J’s Covid-19 shot was, however, very effective against severe and critical cases in South Africa. The vaccine was 73.1% effective in preventing such cases occurring at least 14 days after vaccination, and 81.7% effective in preventing such cases at least 28 days after vaccination.

How Viral Vector Vaccines Work

Johnson & Johnson’s vaccine relies on a different mechanism for conferring immunity than traditional vaccines.

Traditional Vaccines

1. In classic vaccines, such as those against measles and polio, the patient is inoculated with weakened or inactivated versions of the virus. This triggers the immune system to produce specialized antibodies that are adapted to recognize the virus.

2. After vaccination, the antibodies remain in the body. If the patient later becomes infected with the actual virus, the antibodies can identify and help neutralize it.

Johnson & Johnson’s Vaccine

Scientists have isolated the genes in coronavirus responsible for producing these spike proteins. The genes are spliced into weakened, harmless versions of other viruses.

Instead of using the whole virus to generate an immune response, these vaccines use only coronavirus’s outer spike proteins, which are what antibodies use to recognize the virus.

Weakened virus with

spike protein genes

When injected into a patient, the genetically engineered viruses enter healthy cells where they produce coronavirus spike proteins.

The spike proteins produced by the cells prompt the immune system to mount a defense, just as with traditional vaccines.

Vaccine-generated antibody response

1. In classic vaccines, such as those against measles and polio, the patient is inoculated with weakened or inactivated versions of the virus. This triggers the immune system to produce specialized antibodies that are adapted to recognize the virus.

2. After vaccination, the antibodies remain in the body. If the patient later becomes infected with the actual virus, the antibodies can identify and help neutralize it.

Johnson & Johnson’s Vaccine

Scientists have isolated the genes in coronavirus responsible for producing these spike proteins. The genes are spliced into weakened, harmless versions of other viruses.

Instead of using the whole virus to generate an immune response, these vaccines use only coronavirus’s outer spike proteins, which are what antibodies use to recognize the virus.

Weakened virus with

spike protein genes

When injected into a patient, the genetically engineered viruses enter healthy cells where they produce coronavirus spike proteins.

The spike proteins produced by the cells prompt the immune system to mount a defense, just as with traditional vaccines.

Vaccine-generated antibody response

1. In classic vaccines, such as those against measles and polio, the patient is inoculated with weakened or inactivated versions of the virus. This triggers the immune system to produce specialized antibodies that are adapted to recognize the virus.

2. After vaccination, the antibodies remain in the body. If the patient later becomes infected with the actual virus, the antibodies can identify and help neutralize it.

Johnson & Johnson’s Vaccine

Scientists have isolated the genes in coronavirus responsible for producing these spike proteins. The genes are spliced into weakened, harmless versions of other viruses.

Instead of using the whole virus to generate an immune response, these vaccines use only coronavirus’s outer spike proteins, which are what antibodies use to recognize the virus.

Weakened virus with

spike protein genes

When injected into a patient, the genetically engineered viruses enter healthy cells where they produce coronavirus spike proteins.

The spike proteins produced by the cells prompt the immune system to mount a defense, just as with traditional vaccines.

Vaccine-generated antibody response

1. In classic vaccines, such as those against measles and polio, the patient is inoculated with weakened or inactivated versions of the virus. This triggers the immune system to produce specialized antibodies that are adapted to recognize the virus.

2. After vaccination, the antibodies remain in the body. If the patient later becomes infected with the actual virus, the antibodies can identify and help neutralize it.

Johnson & Johnson’s Vaccine

Instead of using the whole virus to generate an immune response, these vaccines use only coronavirus’s outer spike proteins, which are what antibodies use to recognize the virus.

Scientists have isolated the genes in coronavirus responsible for producing these

spike proteins. The genes are spliced into weakened, harmless versions of other viruses.

Weakened virus with

spike protein genes

When injected into a patient, the genetically engineered viruses enter healthy cells where they produce coronavirus spike proteins.

The spike proteins produced by the cells prompt the immune system to mount a defense, just as with traditional vaccines.

Vaccine-generated antibody response

J&J, citing preliminary evidence in an analysis released by the FDA, said the vaccine was 65.5% effective in preventing asymptomatic infections in a subset of study subjects.

Health authorities have been watching whether Covid-19 shots can stop people without symptoms from transmitting the virus. The virus has largely been spread by people who were infected but didn’t realize it because they had no symptoms.

The vaccine was less effective in South Africa, where a more-transmissible Covid-19 variant has thrived, than in the U.S. J&J is among the companies working on new shots targeting the new strain, which several current vaccines don’t appear to work as well against.

Write to Thomas M. Burton at [email protected] and Peter Loftus at [email protected]

Copyright ©2020 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8



Source link

Categories
Reviews

States ranked by percentage of COVID-19 vaccines administered: Jan. 25


North Dakota has administered the highest percentage of COVID-19 vaccines it has received, according to the CDC’s COVID-19 vaccine distribution and administration data tracker.

The CDC’s data tracker compiles data from healthcare facilities and public health authorities. It updates daily to report the total number of COVID-19 vaccines that have been distributed to each state and the total number each state has administered.

As of 6 a.m. EST Jan. 24, a total of 41,411,550 vaccine doses have been distributed in the U.S., and 21,848,655 have been administered, or 52.76 percent. That means about 6.66 percent of the U.S. population has been vaccinated. Additionally, 18,502,131 people have received their first dose of the vaccine, and 3,216,836 have received the full two doses. 

Below are the states ranked by the percentage of COVID-19 vaccines they’ve administered of those that have been distributed to them. Some numbers may not reflect the actual number of vaccines administered, as coding problems and data lags have hindered efforts to accurately count and publicly report how many doses are administered daily in some states. 

  1. North Dakota
    Doses distributed to state: 86,750
    Doses administered: 73,175
    Percentage of distributed vaccines that have been administered: 84.35
  2. West Virginia
    Doses distributed to state: 243,100
    Doses administered: 202,883
    Percentage of distributed vaccines that have been administered: 83.46
  3. New Mexico
    Doses distributed to state: 257,075
    Doses administered: 200,141
    Percentage of distributed vaccines that have been administered: 77.85
  4. South Dakota
    Doses distributed to state: 106,575
    Doses administered: 80,441
    Percentage of distributed vaccines that have been administered: 75.48
  5. Connecticut
    Doses distributed to state: 492,850
    Doses administered: 321,737
    Percentage of distributed vaccines that have been administered: 65.28
  6. Oklahoma
    Doses distributed to state: 496,350
    Doses administered: 322,810
    Percentage of distributed vaccines that have been administered: 65.04
  7. Montana
    Doses distributed to state: 119,500
    Doses administered: 76,590
    Percentage of distributed vaccines that have been administered: 64.09
  8. Kentucky
    Doses distributed to state: 471,000
    Doses administered: 299,493
    Percentage of distributed vaccines that have been administered: 63.59
  9. Michigan
    Doses distributed to state: 1,095,675
    Doses administered: 695,273
    Percentage of distributed vaccines that have been administered: 63.46
  10. Colorado
    Doses distributed to state: 692,700
    Doses administered: 434,496
    Percentage of distributed vaccines that have been administered: 62.72
  11. South Carolina
    Doses distributed to state: 453,250
    Doses administered: 278,795
    Percentage of distributed vaccines that have been administered: 61.51
  12. Louisiana
    Doses distributed to state: 543,700
    Doses administered: 334,086
    Percentage of distributed vaccines that have been administered: 61.45
  13. Alaska
    Doses distributed to state: 155,700
    Doses administered: 94,257
    Percentage of distributed vaccines that have been administered: 60.54
  14. Utah
    Doses distributed to state: 341,725
    Doses administered: 202,729
    Percentage of distributed vaccines that have been administered: 59.33
  15. Arkansas
    Doses distributed to state: 368,650
    Doses administered: 214,240
    Percentage of distributed vaccines that have been administered: 58.11
  16. Oregon
    Doses distributed to state: 492,450
    Doses administered: 285,922
    Percentage of distributed vaccines that have been administered: 58.06
  17. Wyoming
    Doses distributed to state: 70,750
    Doses administered: 40,803
    Percentage of distributed vaccines that have been administered: 57.67
  18. Vermont
    Doses distributed to state: 90,000
    Doses administered: 51,872
    Percentage of distributed vaccines that have been administered: 57.64
  19. Texas
    Doses distributed to state: 3,070,825
    Doses administered: 1,763,299
    Percentage of distributed vaccines that have been administered: 57.42
  20. New Hampshire
    Doses distributed to state: 162,950
    Doses administered: 93,338
    Percentage of distributed vaccines that have been administered: 57.28
  21. New York
    Doses distributed to state: 2,395,950
    Doses administered: 1,365,404
    Percentage of distributed vaccines that have been administered: 56.99
  22. Maine
    Doses distributed to state: 178,450
    Doses administered: 99,815
    Percentage of distributed vaccines that have been administered: 55.93
  23. Nebraska
    Doses distributed to state: 238,100
    Doses administered: 132,846
    Percentage of distributed vaccines that have been administered: 55.79
  24. Delaware
    Doses distributed to state: 116,325
    Doses administered: 64,186
    Percentage of distributed vaccines that have been administered: 55.18
  25. New Jersey
    Doses distributed to state: 989,900
    Doses administered: 535,625
    Percentage of distributed vaccines that have been administered: 54.11
  26. Tennessee
    Doses distributed to state: 838,825
    Doses administered: 452,042
    Percentage of distributed vaccines that have been administered: 53.89
  27. Florida
    Doses distributed to state: 2,908,275|
    Doses administered: 1,544,794
    Percentage of distributed vaccines that have been administered: 53.12
  28. Washington
    Doses distributed to state: 846,625
    Doses administered: 449,385
    Percentage of distributed vaccines that have been administered: 53.08
  29. Nevada
    Doses distributed to state: 286,950
    Doses administered: 152,203
    Percentage of distributed vaccines that have been administered: 53.04
  30. Indiana
    Doses distributed to state: 841,725
    Doses administered: 446,029
    Percentage of distributed vaccines that have been administered: 52.99
  31. Iowa
    Doses distributed to state: 361,475
    Doses administered: 191,183
    Percentage of distributed vaccines that have been administered: 52.89
  32. Ohio
    Doses distributed to state: 1,233,075
    Doses administered: 647,104
    Percentage of distributed vaccines that have been administered: 52.48
  33. North Carolina
    Doses distributed to state: 1,246,600
    Doses administered: 636,439
    Percentage of distributed vaccines that have been administered: 51.05
  34. Wisconsin
    Doses distributed to state: 610,100
    Doses administered: 308,290
    Percentage of distributed vaccines that have been administered: 50.53
  35. Mississippi
    Doses distributed to state: 358,100
    Doses administered: 177,636
    Percentage of distributed vaccines that have been administered: 49.61
  36. Illinois
    Doses distributed to state: 1,417,250
    Doses administered: 699,072
    Percentage of distributed vaccines that have been administered: 49.33
  37. Georgia
    Doses distributed to state: 1,235,775
    Doses administered: 604,067
    Percentage of distributed vaccines that have been administered: 48.88
  38. Massachusetts
    Doses distributed to state: 859,175
    Doses administered: 419,806
    Percentage of distributed vaccines that have been administered: 48.86
  39. Idaho
    Doses distributed to state: 181,100
    Doses administered: 87,128
    Percentage of distributed vaccines that have been administered: 48.11
  40. Missouri
    Doses distributed to state: 661,400
    Doses administered: 317,737
    Percentage of distributed vaccines that have been administered: 48.04
  41. Pennsylvania
    Doses distributed to state: 1,564,125
    Doses administered: 744,591
    Percentage of distributed vaccines that have been administered: 47.60
  42. Minnesota
    Doses distributed to state: 680,700
    Doses administered: 321,180
    Percentage of distributed vaccines that have been administered: 47.18
  43. Arizona
    Doses distributed to state: 829,500
    Doses administered: 390,623
    Percentage of distributed vaccines that have been administered: 47.09
  44. Alabama
    Doses distributed to state: 521,225
    Doses administered: 243,737
    Percentage of distributed vaccines that have been administered: 46.76
  45. Maryland
    Doses distributed to state: 742,175
    Doses administered: 338,544
    Percentage of distributed vaccines that have been administered: 45.62
  46. Rhode Island
    Doses distributed to state: 149,225
    Doses administered: 67,566
    Percentage of distributed vaccines that have been administered: 45.28
  47. California
    Doses distributed to state: 4,906,525
    Doses administered: 2,199,908
    Percentage of distributed vaccines that have been administered: 44.84
  48. Hawaii
    Doses distributed to state: 191,575
    Doses administered: 84,792
    Percentage of distributed vaccines that have been administered: 44.26
  49. Kansas
    Doses distributed to state: 348,175
    Doses administered: 151,249
    Percentage of distributed vaccines that have been administered: 43.44
  50. Virginia
    Doses distributed to state: 1,069,725
    Doses administered: 451,668
    Percentage of distributed vaccines that have been administered: 42.22

More articles on public health:
Mixing COVID-19 vaccine doses OK in rare situations, CDC says
Some evidence indicates UK strain is more deadly, Boris Johnson says
COVID-19 hospitalizations by state: Jan. 25

 


© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.



Source link

Categories
Future

Dow Slips Amid New Travel Curbs


The index of blue-chip stocks fell 200.94 points, or 0.7%, to 30015.51, marking its largest one-day point and percentage decline in December. The S&P 500 slid 7.66 points, or 0.2%, to 3687.26 to extend its losing streak to a third session.

The tech-heavy Nasdaq Composite, in contrast, rose 65.40 points, or 0.5%, to 12807.92, a new all-time high.

Much of the stock market has lost steam this week as some nations began taking steps to curtail travel in an effort to contain the emergence of a fast-spreading variant of coronavirus from England. The U.K. imposed stringent restrictions on social and business activity, prompting concern that more countries may be required to adopt measures that would hamper the global economic recovery.

“It would be a brave man to suggest this will just remain a U.K.-specific issue,” said

Derek Halpenny,

head of research for global markets in the European region at MUFG Bank. “Are we going back into another phase of more pronounced global lockdowns again?”

Oil prices slipped for a second day amid growing worries over the new restrictions imposed on travelers from the U.K. to other countries. Brent crude futures, the benchmark in international energy markets, dropped 1.6% to $50.08 a barrel.

Meanwhile, the yield on the 10-year note ticked down to 0.917%, from 0.941% Monday, as some investors looked to the relative safety of U.S. government bonds. Yields fall when prices rise.

Investors are trying to gauge whether the new strain of Covid-19 will impact the efficacy of vaccines that are being rolled out this month.

BioNTech

Chief Executive

Ugur Sahin

said the vaccine developed by his company, in partnership with

Pfizer,

would likely work against the new variant and is being tested. If a new mutation would make the current vaccine ineffective, BioNTech can develop another tailored to the new variant in six weeks, he said.

Technology stocks traded higher on Nasdaq, in contrast to declines for the S&P and Dow.



Photo:

Michael Nagle/Bloomberg News

“The big unknown is to what degree could the new strain make the efficacy of the vaccine lower,” said

Peter Garnry,

head of equity strategy at Saxo Bank. “If it just turns out to be more infections, and it doesn’t have an effect on the vaccine, then the market will be less concerned.”

Late Monday, a fresh $900 billion fiscal stimulus package was passed by Congress, ending weeks of anticipation from investors about whether lawmakers could end their stalemate. The bill, which includes direct checks to households and relief for small businesses, is expected to be signed by

President Trump.

Even so, the bill’s passage wasn’t enough to propel the broader stock market higher.

“We’ve had the positive news on the vaccines and the fiscal deal, so there’s probably not a catalyst to drive stocks meaningfully higher in the next few weeks,” said

Brian Levitt,

global market strategist at Invesco.

When Is the Market on Holiday?

Select stock-market closures through year’s end

  • Thurs. Dec. 24: U.S. stock market closes at 1 p.m. ET
  • Fri. Dec. 25: Markets closed
  • Mon. Dec. 28: London stock market closed
  • Fri. Jan. 1: Markets closed

Still, Mr. Levitt noted that he maintains a positive outlook on equities.

“In my opinion, betting against stocks over the next year and beyond is betting against medicine, science and policy makers,” he said. “And I’m not willing to make those bets.”

In corporate news,

Apple

rose $3.65, or 2.9%, to $131.88 after Reuters reported that the iPhone maker intends to move forward with its own self-driving car technology.

Exercise-equipment maker

Peloton Interactive

gained $16.82, or 12%, to $161.21, hitting a new all-time-high, after it agreed to buy commercial fitness-equipment provider Precor for $420 million in cash.

Travel stocks and shares of energy companies tumbled.

Norwegian Cruise Line Holdings

slid $1.70, or 6.9%, to $23.08.

Chevron

fell for an eighth consecutive day, losing $1.73, or 2%, to $84.36. That marks the longest losing streak for the oil giant since October 2013.

Meanwhile,

Tesla

tumbled $9.52, or 1.5%, to $640.34, extending its losses for the week to nearly 8%. The electric-car maker made its S&P 500 debut Monday.

Moves in stocks could be big and markets may be especially choppy in coming days because fewer people are trading as the holiday period starts, said

Salman Ahmed,

global head of macro at Fidelity International.

The final stretch of trading in December is historically positive for the stock market. But this week’s losses may be a sign that investors are starting to take profits after a blockbuster year, especially as they consider the possibility of tax changes after President-elect

Joe Biden

takes office, said

JJ Kinahan,

chief market strategist at TD Ameritrade. The S&P 500 is up 14% in 2020, and the Nasdaq Composite has catapulted 43% higher.

Footage shows empty supermarket shelves while trucks bearing cargo get stuck at the border after France imposed a travel ban on Britain following the spread of a new coronavirus strain. Other countries have also barred passengers from the U.K. Photo: Neil Hall/EPA/Shutterstock

Additionally, Mr. Kinahan noted, Tuesday’s worse-than-expected consumer confidence report may also be weighing on markets.

The Conference Board, a private research group, said its index of consumer confidence dropped to 88.6 in the first two weeks of December, from a revised 92.9 in November. Economists surveyed by The Wall Street Journal had expected a level of 97.5.

Still, there were small signs of optimism. Data from the Commerce Department showed Tuesday that U.S. gross domestic product—the value of all goods and services produced across the economy—increased at an annualized rate of 33.4% in the third quarter, slightly stronger than the previous estimate issued last month.

Overseas, European shares rebounded after Monday’s losses. The pan-continental Stoxx Europe 600 gained 1.2%.

Major stock indexes in Asia closed lower. China’s Shanghai Composite fell 1.9%, and South Korea’s Kospi declined 1.6%.

Write to Caitlin Ostroff at [email protected] and Caitlin McCabe at [email protected]

Copyright ©2020 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8



Source link

Categories
Future

Dow Futures Are Softer Amid a Fed and Treasury Clash


Text size



Source link

Categories
Reviews

What southern Coloradans need to know about COVID-19 this week


COLORADO SPRINGS — With so much information being announced daily about the COVID-19 pandemic, here is a review and preview of what is going on in Southern Colorado as it pertains to the virus:

The Review

El Paso County to move to Safer at Home Level 3 restrictions on Friday

El Paso County moved to Safer at Home: Level 3 on the state COVID-19 last Friday. The move follows recent increases in COVID-19 case rates, test positivity, and hospitalizations.

The CDPHE has given the county until 5 p.m. on Friday, Nov. 13 to implement necessary changes.

Pueblo County moving into “high risk” on state dial Saturday

Pueblo County Department of Public Health officials announced last Thursday that the county would be moving into the “high risk” level on the state COVID-19 dial Saturday.

The move to a more restrictive level means the county will lose its variances, which could result in the closure of some businesses. Other businesses may have further limits or restrictions on capacity. In the “high risk” level, capacity is set at 25%.

El Paso County to launch campaign in fight against COVID-19

El Paso County officials are launching an educational campaign as cases of COVID-19 continue to rise.

The county said #SmallActs, the campaign kicking off Monday, will encourage residents to perform small acts “that can make a big impact on stopping the spread of the coronavirus cases.”

Gov. Jared Polis extends statewide mask mandate for another 30 days

Gov. Jared Polis discussed COVID-19 vaccines and extended the statewide mask mandate for another 30 days.

This follows Thursday’s press conference where Colorado’s state epidemiologist said that she believes coronavirus is circulating at its highest levels yet in the state as hospitalizations here have also topped their April high point.

Local school districts returning to online learning

Many local school districts have made the decision to return to online learning for the remainder of the fall semester.

Both Pueblo Districts 60 and 70 have done so, as have Colorado Springs School Districts 11, 20, and 49.

Pfizer says its COVID-19 vaccine candidate is 90% effective

Pfizer announced Monday that its COVID-19 vaccine candidate has been 90% effective.

In a press release, the company said that in Phase 3 trials, the vaccine has proven to promote a vaccine efficacy rate above 90% following the two-shot regimen.

Pfizer is already in the process of producing millions of doses of its vaccine candidate after the U.S. government agreed to pay $1.95 billion for 100 million doses of the vaccine, should it prove effective. If and when the FDA grants approval for the vaccine, it will be distributed to hospitals around the country by the U.S. military in an effort the Trump administration has dubbed “Operation Warp Speed.”

The Preview

The Rebound Colorado

On Monday, Elizabeth Watts will take you to the Backyard Marked in Black Forest. It’s a farmer’s market that actually started during the pandemic. She’ll show you how they plan to make things work through the winter months.

On Tuesday, Patrick Nelson will introduce you to a family that is doing their best to celebrate Thanksgiving together and what they’re going through to make that happen. You’ll also hear from experts on ways to keep your gatherings as safe as possible.

Then on Thursday, Patrick will show tell you about the current crisis for daycares. Ten percent have closed during the pandemic. He’ll explain why and also how a non-partisan group is doing what they can to protect daycare centers during these tough times.

_____

With The Rebound Colorado, News5’s team will be here to answer your questions, bringing you expert advice to balance the books, pay the bills, and rebuild savings accounts. E-mail us any time at [email protected] with your suggestions, feedback, frustrations, ideas, suggestions, and anything else you need.

The Rebound Colorado





Source link